Islasertib is under clinical development by Thryv Therapeutics and currently in Phase II for Arrhythmias. According to GlobalData, Phase II drugs for Arrhythmias have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Islasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Islasertib overview
2-MMB program is under development for the treatment of long QT syndrome (arrhythmia). 2-MMB might act on sodium channels to shorten the ventricular action potential durations (APDs). It works by a mechanism distinct from the correction of defective channel trafficking. It is administered by oral route.
Thryv Therapeutics overview
Thryv Therapeutics is a biopharmaceutical company discovering and developing inhibition therapies for long QT syndrome and various cardiovascular diseases. Thryv Therapeutics is headquartered in Newton Center, Massachusetts, the US.
For a complete picture of Islasertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
